Printer Friendly

GENETICS INSTITUTE AND YAMANOUCHI FORM EUROPEAN PARTNERSHIP

 CAMBRIDGE, Mass., May 19 /PRNewswire/ -- Genetics Institute, Inc. (NASDAQ: GENIZ) and Yamanouchi Pharmaceutical Company, Ltd. announced today the formation of GI-Yamanouchi European Partnership. The partnership, organized in the Netherlands, will operate primarily to commercialize bone growth products in Europe.
 In 1990, Genetics Institute and Yamanouchi formed a development partnership to fund the development of Genetics Institute's bone growth factors (BMPs) worldwide. Also in 1990, Genetics Institute and Yamanouchi formed GI-Yamanouchi, Inc., a joint-venture company in Japan, to commercialize BMPs and other products in that country.
 Genetics Institute licensed worldwide BMP marketing rights to the development partnership in 1990. Since then, the development partnership has licensed marketing rights to rhBMP-2, the first of Genetics Institute's BMPs to enter clinical trials, to Genetics Institute for North America, GI-Yamanouchi, Inc. for Japan and now to GI-Yamanouchi European Partnership for Europe. Genetics Institute retains worldwide manufacturing rights for the BMPs and will supply the respective marketing parties with product for both clinical and commercial purposes.
 Genetics Institute, through its newly established Paris office, will have primary responsibility for the GI-Yamanouchi European Partnership in the areas of clinical trials and pan-European market development of the first BMP products for localized bone repair. Yamanouchi will also participate in these efforts.
 Genetics Institute and Yamanouchi have further agreed to use the extensive marketing infrastructure of Brocades Pharma, a wholly- owned subsidiary of Yamanouchi, and Wyeth-Ayerst International, Inc., the international pharmaceutical division of American Home Products Corporation, to sell and distribute the European Partnership's products.
 "We are very excited about this expanded relationship with Yamanouchi," said Tuan Ha-Ngoc, executive vice president, Genetics Institute. "This partnership marks tangible progress toward our goal of becoming a global biopharmaceutical company. We look forward to beginning clinical trials of rhBMP-2 in Europe," he said. Clinical trials of rhBMP-2 began in the U.S. in 1992 and are now underway in Japan.
 "Yamanouchi aims to be a truly global, R&D oriented, pharmaceutical company by the first decade of the 21st century," said Teruhisa Noguchi, Ph.D., executive vice president of Yamanouchi. "We, too, trust the expansion of our relationship with Genetics Institute will contribute significantly to our pursuit of that goal," he continued.
 Genetics Institute is a leading biopharmaceutical firm engaged in the discovery and development of human pharmaceuticals through recombinant DNA and other technologies. The company has a diversified portfolio of licensed and proprietary products at various stages of development, including treatments for anemia, hemophilia, cancer, bone damage, heart disease, inflammatory conditions, and immune system disorders.
 American Home Products Corporation (NYSE:AHP) holds a majority interest in Genetics Institute. AHP is a world leader in the marketing and manufacturing of prescription drugs, medical supplies, diagnostics, over-the-counter medicines and food products.
 Yamanouchi Pharmaceutical Co., Ltd., a leader in Japan's growing pharmaceutical industry, is a research-oriented company headquartered in Tokyo. Yamanouchi and its group companies comprise a comprehensive health care enterprise with over 7,000 employees around the world engaged in research, manufacturing and marketing of a broad range of ethical drugs and a variety of health- oriented consumer products.
 -0- 5/19/93
 /CONTACT: Dennis Harp or Gina Brazier, corporate communications, 617-876-1170/
 (GENIZ)


CO: Genetics Institute, Inc.; Yamanouchi Pharmaceutical Company, Ltd. ST: Massachusetts IN: MTC SU: JVN

DJ -- NE003 -- 0153 05/19/93 09:20 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 19, 1993
Words:544
Previous Article:MUSICLAND FILES SENIOR SUBORDINATED NOTES OFFERING
Next Article:ANALOG DEVICES' SALES UP 14 PERCENT; NET INCOME RISES 160 PERCENT
Topics:


Related Articles
GENETICS INSTITUTE COMMENCES DEVELOPMENT OF NEW BLOOD CELL GROWTH AND STIMULATORY FACTOR
DR. SHELDON M. WOLFF JOINS GENETICS INSTITUTE BOARD
TRANSKARYOTIC THERAPIES AND GENETICS INSTITUTE COLLABORATE ON COMMERCIALIZATION OF GENE THERAPY PRODUCT FOR HEMOPHILIA A
GENETICS INSTITUTE ANNOUNCES OFFICER CHANGES
OXFORD MOLECULAR GROUP ANNOUNCES COLLABORATIVE RESEARCH AGREEMENT WITH YAMANOUCHI PHARMACEUTICAL
GENETICS INSTITUTE, STRYKER AND CREATIVE BIOMOLECULES CROSS-LICENSE KEY BMP/OP PATENTS
CREATIVE BIOMOLECULES, STRYKER AND GENETICS INSTITUTE CROSS-LICENSE KEY BMP/OP PATENTS
Genetics Institute Partners with Chiron and Genentech to Create New Functional Genomics Approach
Genetics Institute Signs Functional Genomics Agreement With Kirin
Structural Bioinformatics Inc. Initiates Drug Discovery Partnership With Yamanouchi Pharmaceutical Co., Ltd.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters